Previous 10 | Next 10 |
Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Plinio - Chief Commercial Officer Jonathan Zung - Chief Development Officer Conference Call Participan...
–Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies– –Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021– –Preclinical data support development of EDP1867 in neuroinflammator...
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference cal...
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change PR Newswire CAMBRIDGE, Mass. , Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the p...
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis– –Data support development of EDP186...
Gainers: Protagonist Therapeutics (NASDAQ:PTGX) +82%, Adamas Pharmaceuticals (NASDAQ:ADMS) +74%, Flexion Therapeutics (NASDAQ:FLXN) +62%, Evelo Biosciences (NASDAQ:EVLO) +16%, Progenity (NASDAQ:PROG) +16%. Losers: Voyager Therapeutics (NASDAQ:VYGR)...
Gainers: Sonoma Pharmaceuticals (NASDAQ:SNOA) +33%, Evelo Biosciences (NASDAQ:EVLO) +12%, ZIVO Bioscience (NASDAQ:ZIVO) +12%, Viridian Therapeutics (NASDAQ:VRDN) +7%, Harpoon Therapeutics (NASDAQ:HARP) +7%. Losers: Altimmune (NASDAQ:ALT) -20%, ...
–Clinically and statistically significant improvement in PASI-50 score achieved– –EDP1815 safety and tolerability data comparable to placebo in study– –EDP1815 advancing towards registration studies in psoriasis– –Management to host con...
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monda...
Gainers: Helbiz HLBZ +135%. Corvus Pharmaceuticals CRVS +77%. Innate Pharma IPHA +37%. Worksport (OTCQB:WKSP) +20%. Priority Technology Holdings (NASDAQ:PRTH) +15%. Entasis Therapeutics (NASDAQ:ETTX) +15%. Capital Senior Living Corporation (NYSE:CSU) +13%. Evelo (NASDAQ:EVLO) +...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...